Back to List View Graph View

Fibroblast activation protein

Fibroblast activation protein (FAP), also called fibroblast activation protein-α, is a cell-surface protein associated particularly with cancer-associated fibroblasts and activated tumor stroma.

Where the papers sit

13 papers from the last 6 months study fibroblast activation protein directly · updated from PubMed 13 Nov 2026

  • FAP PET Imaging

    FAP PET imaging is progressing through probe optimization and early clinical translation. 68Ga-labeled inhibitors, FXX489, Dar3A derivatives, FAPI-46, and 18F-AlF-FAPI-74 are being refined for tumor uptake, circulation, biodistribution, and image quality. PEGylation, albumin-complex stability, and dual targeting aim to extend circulation or improve lesion contrast. Clinical applications are expanding from tumor visualization to peritoneal cancer staging and glioblastoma precision imaging.

    6 papers · 46.2%

  • FAP-Targeted Radiotheranostics

    FAP-targeted radioligands are moving from scaffold design toward tumor-retaining therapeutic agents. 177Lu-DOTA-7ND, FAP-Man, heterobivalent ligands, and FAPI-RGD are assessed for uptake, biodistribution, dosimetry, and tumor growth inhibition. Mannosylation, cyclic-peptide/small-molecule combinations, and dual FAP–integrin targeting seek to improve retention and selectivity. Early first-in-human evidence remains limited, leaving safety and durable clinical benefit open.

    4 papers · 30.8%

  • FAP Tumor Microenvironment

    FAP-associated stromal niches are being linked to immune suppression, treatment resistance, and therapeutic vulnerability in solid tumors. Single-cell and spatial multi-omics highlight tumor–stroma interfaces involving interferon signaling, tumor-associated macrophages, and AXL. FAP×CD3 bispecific antibodies pursue direct T-cell killing, while radioligands seek prolonged retention and metastasis inhibition. The field remains split between mapping resistant niches and testing distinct FAP-directed interventions.

    3 papers · 23.1%

NEW DIRECTION

FAP is presented as a direct glioblastoma-cell target, not only a stromal target

The glioblastoma study using human U-87 MG and murine SB28 models assumed the usual stromal framing in which FAP is a target in the tumor microenvironment, particularly cancer-associated fibroblasts; instead, it reports FAP expression within glioblastoma cells as well as the surrounding microenvironment and evaluates FAPI-46 imaging and radionuclide therapy in both immunocompromised and immunocompetent models. This expands the targetable compartment from FAP-positive stroma to the tumor cells themselves, changing the interpretation of FAP-directed therapy in glioblastoma from stromal targeting alone to potentially combined tumor-cell and stromal targeting 42242868Jun.

Papers

The 13 papers from the last 6 months that study fibroblast activation protein directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

FAP PET Imaging (6)
  1. 68Ga-NOTA-FAPI-IF7: A Heterobivalent PET Probe for Dual-Targeted Imaging of Fibroblast Activation Protein and Annexin A1 in Tumor Microenvironment. Molecular pharmaceutics · 2 Nov 2026 PMID 42969726
  2. First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study. Molecular pharmaceutics · 2 Nov 2026 PMID 42969700
  3. Systematic PEGylation optimization of Dar3A-based FAP-targeted PET probes and first-in-human study. Journal of controlled release : official journal of the Controlled Release Society · 30 Sept 2026 PMID 42815646
  4. [18F]AlF-FAPI-74 PET/CT for preoperative assessment of the peritoneal cancer index and comparison with MRI-based, surgical and pathological assessment in colorectal cancer patients eligible for CRS-HIPEC: study protocol for a prospective observational proof-of-concept study. BMJ open · 9 Sept 2026 PMID 42716685
  5. Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 4 Jun 2026 PMID 42242868
  6. Structural stability of human serum albumin complexes governs the blood circulation of gallium-Labeled FAP inhibitors. Bioorganic chemistry · 22 May 2026 PMID 42172798
FAP-Targeted Radiotheranostics (4)
  1. Design and Biological Evaluation of FAP-Man, a Mannosylated FAP-Targeted Radioglycopeptide for Tumor Imaging and Radionuclide Therapy. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018593
  2. Heterobivalent fibroblast activation protein-targeted Radiotheranostic ligands integrating cyclic peptide and small-molecule motifs for enhanced tumor retention. Bioorganic chemistry · 11 Sept 2026 PMID 42727450
  3. Safety, Biodistribution, and Dosimetry of FAP and Integrin αvβ3 Dual-Targeting Radioligand 177Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 20 Aug 2026 PMID 42624650
  4. Preclinical and first-in-human pilot evaluation of 177Lu-DOTA-7ND for fibroblast activation protein-α-targeted radionuclide imaging and therapy. Journal of controlled release : official journal of the Controlled Release Society · 20 Aug 2026 PMID 42624433
FAP Tumor Microenvironment (3)
  1. Single-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance. Cell reports. Medicine · 16 Sept 2026 PMID 42748914
  2. The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science advances · 11 Sept 2026 PMID 42726846
  3. A 68Ga/161Tb-labeled FAP-targeted radioligand for enhanced theranostics: Prolonged tumor retention and metastasis inhibition. Journal of controlled release : official journal of the Controlled Release Society · 24 Aug 2026 PMID 42636892

By study type

Clinical trials (1)
  1. Safety, Biodistribution, and Dosimetry of FAP and Integrin αvβ3 Dual-Targeting Radioligand 177Lu-DOTA-FAPI-RGD: Preclinical Validation and First-in-Human Study in Patients with Advanced Adenocarcinomas. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 20 Aug 2026 PMID 42624650
Observational studies and case reports (1)
  1. [18F]AlF-FAPI-74 PET/CT for preoperative assessment of the peritoneal cancer index and comparison with MRI-based, surgical and pathological assessment in colorectal cancer patients eligible for CRS-HIPEC: study protocol for a prospective observational proof-of-concept study. BMJ open · 9 Sept 2026 PMID 42716685
Human data, design not indexed (1)
  1. Structural stability of human serum albumin complexes governs the blood circulation of gallium-Labeled FAP inhibitors. Bioorganic chemistry · 22 May 2026 PMID 42172798
Preclinical: animal, cell and lab studies (9)
  1. Design and Biological Evaluation of FAP-Man, a Mannosylated FAP-Targeted Radioglycopeptide for Tumor Imaging and Radionuclide Therapy. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018593
  2. 68Ga-NOTA-FAPI-IF7: A Heterobivalent PET Probe for Dual-Targeted Imaging of Fibroblast Activation Protein and Annexin A1 in Tumor Microenvironment. Molecular pharmaceutics · 2 Nov 2026 PMID 42969726
  3. First-in-Human PET/CT Imaging of FXX489, a Second-Generation Cyclic Peptide FAP Inhibitor: A Translational Exploratory Study. Molecular pharmaceutics · 2 Nov 2026 PMID 42969700
  4. Systematic PEGylation optimization of Dar3A-based FAP-targeted PET probes and first-in-human study. Journal of controlled release : official journal of the Controlled Release Society · 30 Sept 2026 PMID 42815646
  5. Heterobivalent fibroblast activation protein-targeted Radiotheranostic ligands integrating cyclic peptide and small-molecule motifs for enhanced tumor retention. Bioorganic chemistry · 11 Sept 2026 PMID 42727450
  6. The FAP × CD3 bispecific antibody OMTX305 induces T cell-mediated antitumor effects in patient-derived ex vivo models of solid tumors. Science advances · 11 Sept 2026 PMID 42726846
  7. A 68Ga/161Tb-labeled FAP-targeted radioligand for enhanced theranostics: Prolonged tumor retention and metastasis inhibition. Journal of controlled release : official journal of the Controlled Release Society · 24 Aug 2026 PMID 42636892
  8. Preclinical and first-in-human pilot evaluation of 177Lu-DOTA-7ND for fibroblast activation protein-α-targeted radionuclide imaging and therapy. Journal of controlled release : official journal of the Controlled Release Society · 20 Aug 2026 PMID 42624433
  9. Translational Theranostics in Glioblastoma: FAPI-46 as a Precision Medicine Tool. Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 4 Jun 2026 PMID 42242868
Unclassified: not yet indexed with MeSH (1)
  1. Single-cell and spatial multi-omics reveal a recurrent multicellular niche at the tumor-stroma interface in multidrug resistance. Cell reports. Medicine · 16 Sept 2026 PMID 42748914